Published in J Antimicrob Chemother on October 01, 2000
Tackling antibiotic resistance. Nat Rev Microbiol (2011) 3.95
Pharmacodynamics of telavancin (TD-6424), a novel bactericidal agent, against gram-positive bacteria. Antimicrob Agents Chemother (2004) 2.17
Daptomycin-oxacillin combinations in treatment of experimental endocarditis caused by daptomycin-nonsusceptible strains of methicillin-resistant Staphylococcus aureus with evolving oxacillin susceptibility (the "seesaw effect"). Antimicrob Agents Chemother (2010) 1.98
Cell wall thickening is not a universal accompaniment of the daptomycin nonsusceptibility phenotype in Staphylococcus aureus: evidence for multiple resistance mechanisms. Antimicrob Agents Chemother (2010) 1.85
In vitro activities of daptomycin, vancomycin, quinupristin- dalfopristin, linezolid, and five other antimicrobials against 307 gram-positive anaerobic and 31 Corynebacterium clinical isolates. Antimicrob Agents Chemother (2003) 1.69
Synergy of daptomycin with oxacillin and other beta-lactams against methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother (2004) 1.47
Chemoenzymatic and template-directed synthesis of bioactive macrocyclic peptides. Microbiol Mol Biol Rev (2006) 1.41
Daptomycin dose-effect relationship against resistant gram-positive organisms. Antimicrob Agents Chemother (2003) 1.38
Bactericidal activities of daptomycin, quinupristin-dalfopristin, and linezolid against vancomycin-resistant Staphylococcus aureus in an in vitro pharmacodynamic model with simulated endocardial vegetations. Antimicrob Agents Chemother (2003) 1.21
Effect of divalent cations on the structure of the antibiotic daptomycin. Eur Biophys J (2007) 1.17
Evaluation of high-dose daptomycin for therapy of experimental Staphylococcus aureus foreign body infection. BMC Infect Dis (2006) 1.14
Broad-spectrum antibiotic activity of the arylomycin natural products is masked by natural target mutations. Chem Biol (2010) 1.13
Daptomycin in bone and joint infections: a review of the literature. Arch Orthop Trauma Surg (2008) 1.11
Increased killing of staphylococci and streptococci by daptomycin compared with cefazolin and vancomycin in an in vitro peritoneal dialysate model. Antimicrob Agents Chemother (2003) 1.09
Biochemical characterization of cardiolipin synthase mutations associated with daptomycin resistance in enterococci. Antimicrob Agents Chemother (2012) 1.03
Baseline study to determine in vitro activities of daptomycin against gram-positive pathogens isolated in the United States in 2000-2001. Antimicrob Agents Chemother (2003) 1.00
Efficacy profiles of daptomycin for treatment of invasive and noninvasive pulmonary infections with Streptococcus pneumoniae. Antimicrob Agents Chemother (2009) 0.98
Database-Guided Discovery of Potent Peptides to Combat HIV-1 or Superbugs. Pharmaceuticals (Basel) (2013) 0.90
Daptomycin versus linezolid for treatment of vancomycin-resistant enterococcal bacteremia: systematic review and meta-analysis. BMC Infect Dis (2014) 0.88
Safety and efficacy of high-dose daptomycin as salvage therapy for severe gram-positive bacterial sepsis in hospitalized adult patients. BMC Infect Dis (2013) 0.88
Frequency and Distribution of Single-Nucleotide Polymorphisms within mprF in Methicillin-Resistant Staphylococcus aureus Clinical Isolates and Their Role in Cross-Resistance to Daptomycin and Host Defense Antimicrobial Peptides. Antimicrob Agents Chemother (2015) 0.85
The Advantage of Bactericidal Drugs in the Treatment of Infection. Curr Infect Dis Rep (2004) 0.85
Daptomycin: a novel lipopeptide antibiotic against Gram-positive pathogens. Infect Drug Resist (2010) 0.84
Isolation and characterization of diverse antimicrobial lipopeptides produced by Citrobacter and Enterobacter. BMC Microbiol (2013) 0.83
A novel lipopeptide from skin commensal activates TLR2/CD36-p38 MAPK signaling to increase antibacterial defense against bacterial infection. PLoS One (2013) 0.82
Mechanism of bactericidal activity of silver nitrate - a concentration dependent bi-functional molecule. Braz J Microbiol (2010) 0.81
The safety and efficacy of daptomycin versus other antibiotics for skin and soft-tissue infections: a meta-analysis of randomised controlled trials. BMJ Open (2014) 0.80
Musculoskeletal safety outcomes of patients receiving daptomycin with HMG-CoA reductase inhibitors. Antimicrob Agents Chemother (2014) 0.80
High-dose daptomycin therapy for staphylococcal endocarditis and when to apply it. Curr Infect Dis Rep (2014) 0.79
DepR1, a TetR Family Transcriptional Regulator, Positively Regulates Daptomycin Production in an Industrial Producer, Streptomyces roseosporus SW0702. Appl Environ Microbiol (2016) 0.77
Daptomycin for the treatment of major gram-positive infections after cardiac surgery. J Cardiothorac Surg (2016) 0.77
antibacTR: dynamic antibacterial-drug-target ranking integrating comparative genomics, structural analysis and experimental annotation. BMC Genomics (2014) 0.77
Bacteremia and endocarditis due to methicillin-resistant Staphylococcus aureus: the potential role of daptomycin. Ther Clin Risk Manag (2007) 0.77
A review of daptomycin for injection (Cubicin) in the treatment of complicated skin and skin structure infections. Ther Clin Risk Manag (2006) 0.76
Structure-activity studies of divin: an inhibitor of bacterial cell division. ACS Med Chem Lett (2013) 0.75
Improved production of Daptomycin in an airlift bioreactor by morphologically modified and immobilized cells of Streptomyces roseosporus. AMB Express (2016) 0.75
Membrane Active Antimicrobial Peptides: Translating Mechanistic Insights to Design. Front Neurosci (2017) 0.75
Bioprospecting Red Sea Coastal Ecosystems for Culturable Microorganisms and Their Antimicrobial Potential. Mar Drugs (2016) 0.75
Activity of daptomycin against recent North American isolates of Streptococcus pneumoniae. Antimicrob Agents Chemother (2003) 0.75
Identification, synthesis and biological activity of alkyl-guanidine oligomers as potent antibacterial agents. Sci Rep (2017) 0.75
Daptomycin: a novel agent for Gram-positive infections. Expert Opin Investig Drugs (1999) 2.83
Preliminary evaluation of safety and activity of recombinant human interleukin 11 in patients with active Crohn's disease. Gastroenterology (1999) 1.05
A pilot trial of recombinant interleukin-12 in patients with chronic hepatitis C who previously failed treatment with interferon-alpha. Am J Gastroenterol (2001) 0.77